NDLI: New developments in diabetes management: medications of the 21st century.

Please wait, while we are loading the content...

Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus.

New developments in diabetes management: medications of the 21st century.

Predictors of clinical success among a national Veterans Affairs cohort with methicillin-resistant Staphylococcus aureus pneumonia.

Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.

Costs and length of stay of drug-related hospital admissions in cancer patients.

Use of the Functional Assessment of Cancer Therapy--anemia in persons with myeloproliferative neoplasm-associated myelofibrosis and anemia.

Analysis of chemotherapy dosage and dosage intensity and survival outcomes of high-grade osteosarcoma patients younger than 40 years.

Pulmonary function assessment in mild to moderate persistent asthma patients receiving montelukast, doxofylline, and tiotropium with budesonide: a randomized controlled study.

Onset of response with duloxetine treatment in patients with osteoarthritis knee pain and chronic low back pain: a post hoc analysis of placebo-controlled trials.

Dose efficiency of erythropoiesis-stimulating agents for the treatment of patients with chemotherapy-induced anemia: a systematic review.

Comparative fasting bioavailability of 2 bepotastine formulations in healthy male Chinese volunteers: an open-label, randomized, single-dose, 2-way crossover study.

The effect of weight on the efficacy and safety of C1 esterase inhibitor concentrate for the treatment of acute hereditary angioedema.

Having their say: patients' perspectives and the clinical management of diabetes.

Glucometer use and glycemic control among Hispanic patients with diabetes in southern Florida.

Year: 2014 Volume: 36 Issue: 3

Year: 2014 Volume: 36 Issue: 2

Year: 2014 Volume: 36 Issue: 1

Year: 2013 Volume: 35

Year: 2012 Volume: 34

Year: 2011 Volume: 33

Year: 2010 Volume: 32

Year: 2009 Volume: 31

Year: 2008 Volume: 30

Year: 2008 Volume: 30 Spec No

Year: 2008 Volume: 30 Pt 2

Year: 2007 Volume: 29

New developments in diabetes management: medications of the 21st century.

Content Provider	World Health Organization (WHO)-Global Index Medicus
Author	Fonseca, Vivian A.
Description	Author Affiliation: Fonseca VA ( Section of Endocrinology, Tulane University Medical Center, New Orleans, Louisiana. Electronic address: vfonseca@tulane.edu.)
Abstract	BACKGROUND: Suboptimal blood glucose control among patients with type 2 diabetes continues to support the need for new pharmacologic approaches. OBJECTIVE: The purpose of this commentary was to highlight newly available and soon-to-be available agents that are promising tools for targeting specific pathophysiologic pathways in the management of diabetes. METHODS: Published evidence to support the application of novel incretin-based therapies, dipeptidyl peptidase (DPP)-4 inhibitors, sodium-glucose cotransporter (SGLT)-2 inhibitors, other oral agents and insulins for managing specific aspects of type 2 diabetes, as well as disadvantages associated with those novel medications, are discussed. RESULTS: Several new glucagon-like peptide (GLP)-1 receptor agonists with different time frames of action, although each has unique advantages and disadvantages, have been through clinical trials. Examples of these are lixisenatide and albiglutide. Currently available DPP-4 inhibitor agents, important for inhibiting the breakdown of endogenous GLP-1, have not been associated with weight gain or hypoglycemia. SGLT-2 inhibitors, which do not depend on insulin secretion or insulin action, may be advantageous in that they appear to be broadly efficacious at all stages of diabetes. New insulin analogues, such as degludec and U-500, improve glycemic control without contributing to hypoglycemia. CONCLUSIONS: Advances in pharmacologic options offer the promise of improving glycemic control for longer periods, with limited glycemic fluctuations, hypoglycemia, and weight gain. However, the effectiveness of these agents ultimately depends on their availability to providers managing the health care of patients at high risk for poor diabetes outcomes and patients' use of them as directed. Long-term effectiveness and safety trials are ongoing.
File Format	HTM / HTML
ISSN	01492918
Issue Number	4
Volume Number	36
e-ISSN	1879114X
Journal	Clinical Therapeutics
Language	English
Publisher	Elsevier
Publisher Date	2014-04-01
Publisher Place	United States
Access Restriction	One Nation One Subscription (ONOS)
Subject Keyword	Discipline Pharmacology Diabetes Mellitus, Type 2 Drug Therapy Hypoglycemic Agents Therapeutic Use Blood Glucose Blood Dipeptidyl-peptidase Iv Inhibitors Pharmacology Female Glucagon-like Peptide 1 Analogs & Derivatives Humans Hypoglycemia Chemically Induced Incretins Insulin Insulin, Long-acting Male Peptides Journal Article Review
Content Type	Text
Resource Type	Article
Subject	Pharmacology Pharmacology (medical)

Sl.	Authority	Responsibilities	Communication Details
1	Ministry of Education (GoI), Department of Higher Education	Sanctioning Authority	https://www.education.gov.in/ict-initiatives
2	Indian Institute of Technology Kharagpur	Host Institute of the Project: The host institute of the project is responsible for providing infrastructure support and hosting the project	https://www.iitkgp.ac.in
3	National Digital Library of India Office, Indian Institute of Technology Kharagpur	The administrative and infrastructural headquarters of the project	Dr. B. Sutradhar bsutra@ndl.gov.in
4	Project PI / Joint PI	Principal Investigator and Joint Principal Investigators of the project	Dr. B. Sutradhar bsutra@ndl.gov.in Prof. Saswat Chakrabarti will be added soon
5	Website/Portal (Helpdesk)	Queries regarding NDLI and its services	support@ndl.gov.in
6	Contents and Copyright Issues	Queries related to content curation and copyright issues	content@ndl.gov.in
7	National Digital Library of India Club (NDLI Club)	Queries related to NDLI Club formation, support, user awareness program, seminar/symposium, collaboration, social media, promotion, and outreach	clubsupport@ndl.gov.in
8	Digital Preservation Centre (DPC)	Assistance with digitizing and archiving copyright-free printed books	dpc@ndl.gov.in
9	IDR Setup or Support	Queries related to establishment and support of Institutional Digital Repository (IDR) and IDR workshops	idr@ndl.gov.in

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

DPP4 inhibitors: a new approach in diabetes treatment.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.

Incretin-based therapies. (Journal: Journal of Diabetes Volume: 4 Issue: 1)

Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?

Inkretinek és inkretinhatású vércukorcsökkentok pleiotrop tulajdonságai.

New developments in diabetes management: medications of the 21st century.

Similar Documents

Therapeutic potential of dipeptidyl peptidase-IV inhibitors in patients with diabetes mellitus.

DPP4 inhibitors: a new approach in diabetes treatment.

The pharmacologic basis for clinical differences among GLP-1 receptor agonists and DPP-4 inhibitors.

Novel therapeutics for type 2 diabetes: incretin hormone mimetics (glucagon-like peptide-1 receptor agonists) and dipeptidyl peptidase-4 inhibitors.

Incretin therapies: highlighting common features and differences in the modes of action of glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors.

Combining a dipeptidyl peptidase-4 inhibitor, alogliptin, with pioglitazone improves glycaemic control, lipid profiles and beta-cell function in db/db mice.

Incretin-based therapies. (Journal: Journal of Diabetes Volume: 4 Issue: 1)

Q: Do incretin drugs for type 2 diabetes increase the risk of acute pancreatitis?

Inkretinek és inkretinhatású vércukorcsökkentok pleiotrop tulajdonságai.

New developments in diabetes management: medications of the 21st century.